SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277300.
  • 2
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 143548.
  • 3
    Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988; 139: 2835.
  • 4
    Thurman SA, DeWeese TL. Multimodality therapy for the treatment of muscle-invasive bladder cancer. Semin Urol Oncol 2000; 18: 31322.
  • 5
    Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116: 57580.
  • 6
    Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000; 163: 601; discussion 1–2.
  • 7
    Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005; 66: 6474.
  • 8
    Esrig D, Spruck CH III, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 138997.
  • 9
    Goebell PJ, Groshen SG, Schmitz-Drager BJ. p53 immunohistochemistry in bladder cancer–a new approach to an old question. Urol Oncol 2010; 28: 37788.
  • 10
    Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI. Decreasing of p27(Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001; 84: 124251.
  • 11
    Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000; 31: 75160.
  • 12
    Letarte S, Brusniak MY, Campbell D et al. Differential plasma glycoproteome of p19 skin cancer mouse model using the corra label-free LC-MS proteomics platform. Clin Proteomics 2008; 4: 105.
  • 13
    Tsui KH, Tang P, Lin CY, Chang PL, Chang CH, Yung BY. Bikunin loss in urine as useful marker for bladder carcinoma. J Urol 2010; 183: 33944.
  • 14
    Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 434.
  • 15
    Sui J, Zhang J, Tan TL, Ching CB, Chen WN. Comparative proteomics analysis of vascular smooth muscle cells incubated with S- and R-enantiomers of atenolol using iTRAQ-coupled two-dimensional LC-MS/MS. Mol Cell Proteomics 2008; 7: 100718.
  • 16
    Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette–Guerin. Eur Urol 2009; 56: 82936.
  • 17
    Tsui KH, Juang HH, Lee TH, Chang PL, Chen CL, Yung BY. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin 2008; 29: 36470.
  • 18
    Tzai TS, Tsai YS, Shiau AL, Wu CL, Shieh GS, Tsai HT. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology 2006; 67: 2949.
  • 19
    Higgins JP, Kaygusuz G, Wang L et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007; 31: 67380.
  • 20
    Pryor A, Tung L, Yang Z, Kapadia F, Chang TH, Johnson LF. Growth-regulated expression and G0-specific turnover of the mRNA that encodes URH49, a mammalian DExH/D box protein that is highly related to the mRNA export protein UAP56. Nucleic Acids Res 2004; 32: 185765.
  • 21
    Sugiura T, Sakurai K, Nagano Y. Intracellular characterization of DDX39, a novel growth-associated RNA helicase. Exp Cell Res 2007; 313: 78290.
  • 22
    Abdelhaleem M. Over-expression of RNA helicases in cancer. Anticancer Res 2004; 24: 39513.
  • 23
    Sugiura T, Nagano Y, Noguchi Y. DDX39, upregulated in lung squamous cell cancer, displays RNA helicase activities and promotes cancer cell growth. Cancer Biol Ther 2007; 6: 95764.
  • 24
    Lipponen PK, Eskelinen MJ. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 1995; 121: 3038.
  • 25
    Kumar B, Koul S, Petersen J et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 2010; 70: 83241.
  • 26
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 30314.
  • 27
    Sakano S, Matsuyama H, Takai K et al. Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines. BJU Int 2011; 107: 1598604.